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Tissue-nonspeciﬁc alkaline phosphataseMutations in the tissue-nonspeciﬁc alkaline phosphatase (TNSALP) gene are responsible for hypopho-
sphatasia, an inborn error of bone and teeth metabolism associated with reduced levels of serum alkaline
phosphatase activity. A missense mutation (c.346GNA) of TNSALP gene, which converts Ala to Thr at position
116 (according to standardized nomenclature), was reported in dominantly transmitted hypophosphatasia
patients (A.S. Lia-Baldini et al. Hum Genet. 109 (2001) 99–108). To investigate molecular phenotype of
TNSALP (A116T), we expressed it in the COS-1 cells or Tet-On CHO K1 cells. TNSALP (A116T) displayed not
only negligible alkaline phosphatase activity, but also a weak dominant negative effect when co-expressed
with the wild-type enzyme. In contrast to TNSALP (W, wild-type), which was present mostly as a non-
covalently assembled homodimeric form, TNSALP (A116T) was found to exist as a monomer and
heterogeneously associated aggregates covalently linked via disulﬁde bonds. Interestingly, both themonomer
and aggregate forms of TNSALP (A116T) gained access to the cell surface and were anchored to the cell
membrane via glycosylphosphatidylinositol (GPI). Co-expression of secretory forms of TNSALP (W) and
TNSALP (A116T), which are engineered to replace the C-terminal GPI anchor with a tag sequence (his-tag or
ﬂag-tag), resulted in the release of heteromeric complexes consisting of TNSALP (W)-his and TNSALP
(A116T)-ﬂag. Taken together, these ﬁndings strongly suggest that TNSALP (A116T) fails to fold properly and
forms disulﬁde-bonded aggregates, though it is indeed capable of interacting with the wild-type and reaching
the cell surface, therefore explaining its dominant transmission.mum essential medium; ER,
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Hypophosphatasia is a genetic disease caused by various muta-
tions in the tissue-nonspeciﬁc alkaline phosphatase (TNSALP) gene
[1–4]. To date, a total of 224mutations have been reported worldwide
as of Oct. 2010 (http://www.sesep. uvsq.fr/03_hypo_ mutations.php).
Hypophosphatasia is characterized by reduced levels of serum
alkaline phosphatase activity and defective bone and teeth mineral-
ization. One of two natural substrates which relate to clinicalmanifestation of hypophosphatasia, inorganic pyrophosphate is
thought to play a crucial role as a negative regulator at the site of
mineralization. That is, TNSALP enhances the mineralization by
hydrolyzing pyrophosphate to phosphate, and therefore, decline in
the activity due to mutations in the TNSALP gene leads to various
degrees of hypomineralization [2,3]. Symptom of hypophosphatasia
varies widely and in general its severity is inversely related to serum
alkaline phosphatase levels of the patients. Clinically, hypopho-
sphatasia is classiﬁed into ﬁve major categories depending on the
age at diagnosis: perinatal, infantile, childhood, adult and odonto
forms. Recently, the perinatal form is further divided into lethal and
benign types [4]. Severe hypophosphatasia (perinatal and infantile
forms) is transmitted in an autosomal recessive way, while mild
hypophosphatasia (childhood, adult and odonto forms) is transmitted
in a recessive or dominant way.
Severe hypophosphatasia patients are homozygote or compound
heterozygotes with severe mutations, while mild form results from
compound heterozygosity for severe and moderate mutations or single
heterozygosity for severe mutations [5]. Mutations in TNSALP gene
not only reduce the enzyme activity of TNSALP mutant proteins
to a various degree, but also residual activities often exhibit different
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additional variability in clinical symptoms. Apart from their direct
effects on the catalytic function, TNSALP mutant proteins display a
different magnitude of trafﬁcking defects. We, along with other groups,
have reported that defective trafﬁcking of TNSALP mutant protein
contributes a molecular mechanism of hypophosphatasia [7–12]. In
one extreme case where T is deleted at 1559 of TNSALP cDNA, this
frame-shift TNSALP with an additional 80-amino acid extension at the
C-terminus failed to be modiﬁed by glycosylphosphatidylinositol (GPI)
and resultantly is released into the medium [13,14].
There is an increasing number of mild hypophosphatasia with a
dominant negative effect [5,15–17]. These dominant-type TNSALP
mutants suppress the enzyme activity of TNSALP (W) to a various
degree when they are co-expressed in a cell [5,15–17]. Thus this
inhibition of the enzyme activity implies that TNSALP mutant proteins
with a dominant effect and TNSALP (W) are able to interact with each
other and form heteromeric enzyme complexes. However, molecular
characterization of dominantly inherited TNSALP mutations has not
been studied in detail so far. In this report, we examined the molecular
defect of TNSALP (A116T, according to standardized nomenclature,
where the ATG initiator codon is numbered as 1). Extensive study on
familial pedigree and its laboratory data unequivocally show that
TNSALP (A116T) is dominantly transmitted [17,18]. Also, the co-
expression data showed that TNSALP (A116T) inhibits TNSALP (W)
albeit to a lesser degree compared to other dominant negative mutants
suchasTNSALP (D378V) andTNSALP (G63V) [17]. Surprisingly, ourdata
indicate that the replacement of alanine with threonine at position116
of TNSALP (A116T) renders TNSALP incompetent to form a dimeric
structure and resultant monomeric polypeptides associate with each
other to become disulﬁde-bonded high-molecular mass aggregates.
Moreover, we have also indicated that TNSALP (W) is trapped in the
aggregate of TNSALP (A116T) when they are co-expressed.
2. Materials and methods
2.1. Materials
Express35S35S protein labelingmix (N1000 Ci/mmol)was obtained
from Dupont-New England Nuclear (Boston, MA.), and14C-methylat-
ed proteins and enhanced chemiluminescence (ECL®) Western
blotting detection reagent, peroxidase-conjugated donkey anti-
(rabbit IgG) and Protein A-Sepharose CL-4B from Amersham
Pharmacia Biotech (Arlington Heights, IL, USA); pALTER®-MAX,
Altered sites® II mammalian mutagenesis system from Promega
(Madison, WI, U.S.A.); G418 and pansorbin from Calbiochem (La Jolla
CA, U.S.A.); Lipofectamine Plus Reagent from Invitrogen (Carlsbad, CA,
U.S.A.); phosphatidylinositol-speciﬁc phospholipase C (PI-PLC) from
BIOMOL International, L.P. (Plymouth Meeting, PA, U.S.A.); aprotinin,
baker's yeast alcohol dehydrogenase, bovine serum albumin, doxy-
cycline, and ANTI-FLAG®M2 Agarose from Sigma Chemical Co.
(St. Louis, MO.U.S.A.); Ni-NTA (nickel-nitrilotriacetic acid ) resin and
plasmid Midi-kit from Qiagen (Hilden, Germany); pTRE2 and BD®
CHO-K1 Tet-On cell line and Tet system approved Fetal bovine serum
from Clontech (Palo Alto, CA, U.S.A.); sulphosucciniimidyl N-(D-
biotinyl)-6-aminohexane from Dojindo Laboratories (Kumamoto,
Japan); antipain, chymostatin, elastatinal, leupeptin and pepstatin A
from Protein Research Foundation (Osaka, Japan); bovine liver
catalase and hygromycin from Wako Pure Chemicals (Tokyo, Japan).
Antiserum against recombinant human TNSALP was raised in rabbits
as described previously [19].
2.2. Plasmids and transfection
The pALTER-MAX® encoding TNSALP (W) was constructed as
described previously [9]. Mutations were introduced at speciﬁc sites
using Altered sites® II mammalian mutagenesis system essentiallyaccording to the manufacturer's protocol [10]. Oligonucleotides used
are: TNSALP (A116T), 5′-CCCACACAGGTACGTAGTGGCGGTGCC-3′;
TNSALP (W) his-tag, 5′-GCAGCAAGGCTGCCTGCCTAGTGATGGT-
GATGGTGATGGCTGGCAGGAGCACA-3′; TNSALP (W or A116T) ﬂag-
tag, 5′-GCAGCAAGGCTGCCTGCCTACTTATCGTCGTCATCCTTGTAA-
TCGCTGGCAGGAGCACA-3′. The DNA sequence of the mutation sites
was veriﬁed by DNA sequence analysis. The cDNA encoding TNSALP
(W) or TNSALP (A116T)was further subcloned into pTRE2 to establish
stable cell lines. Transfection and screening of stable cell lines were
performed essentially according to the manufacturer's protocol. Tet-
On cells, which successfully produced TNSALP (W) or the mutant
TNSALP in the presence of doxycycline, but not in its absence, were
identiﬁed using immunoﬂuorescence. Established Tet-On cells were
cultured and passaged in the absence of doxycycline until they were
used for experiments. For immunoblotting or immunoﬂuorescence
studies, the cells were cultured in the presence of 1 μg/ml doxycycline
for 24 h before used. Alternatively, cells were cultured 0.2 μg/ml of
doxycycline for 14 h before biosynthetic experiments. For transient
expression, COS-1 cells [(1.0–1.3)×105 cells/35-mm dish] were
transfected with 0.8 μg of each plasmid using Lipofectamine Plus
according to the manufacturer's protocol as described previously [10]
and the transfected cells were incubated for 24 h in 5% CO2/95% air
incubator before use. COS-1 cells were cultured in Dulbecco's
modiﬁed Eagle's minimum essential medium (DMEM) supplemented
with 10% fetal bovine serum [10].2.3. Metabolic labeling and immunoprecipitation
For pulse-chase experiments, cells were preincubated for 0.5–1 h
in the methionine/cysteine-free DMEM and labeled with 50–100 μCi
of [35S] methionine/cysteine for 0.5 h in the fresh methionine/
cysteine-free MEM. After a pulse period, cells were washed and
chased in the DMEM as described previously [10]. After metabolic
labeling, the medium was removed, and the cells were lysed in 0.5 ml
of lysis buffer [1% (w/v) Triton X-100/0.5% (w/v) sodium deoxycho-
late/0.05% (w/v) SDS in PBS]. A protease inhibitors cocktail (antipain,
aprotinin, chymostatin, elastatinal, leupeptin, pepstatin A) was added
to cell lysates and media (10 μg each/ml). The lysates were incubated
for 20 min at 37 °C to extract TNSALP. The lysates and media were
subjected to immunoisolation as described previously [10]. The
immune complexes/protein A beads were boiled in the absence or
presence of 1% (v/v) 2-mercaptoethanol, and then analyzed by SDS/
PAGE [9% (w/v) gels], followed by ﬂuorography [7]. For sequential
puriﬁcation of soluble forms of heteromeric TNSALPs, the medium
was adjusted to 20 mM imidazole and incubatedwith Ni-chelate resin
in the presence of 20 mM imidazole. After washing the resin with PBS
containing 20 mM imidazole, TNSALP-his was released with PBS
containing 200 mM imidazole. This fraction was diluted 3-fold with
PBS and mixed with anti-ﬂag antibody beads. After washing with PBS
containing 500 mM NaCl and then PBS, TNSALP-ﬂag was released by
boiling in the presence of SDS.2.4. Miscellaneous procedures
Immunoﬂuorescence for alkaline phosphatase was performed as
described previously [9,10]. Electric transfer of proteins and subse-
quent procedures were described as before [19]. Proteins on
membranes were detected with ECL® Western blotting detection
reagents. Cell surface biotinylation and PI-PLC digestion were carried
out as described previously [8,10]. Sucrose-density-gradient centri-
fugation was performed as described previously [8]. Protein and
alkaline phosphatase assays were performed as described previously
[7,10]. One unit of alkaline phosphatase activity is deﬁned as nmoles
of p-nitrophenylphosphate hydrolyzed per min at 37 °C.
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3.1. Transient expression of TNSALP (A116T) in COS-1 cells
In order to deﬁne the molecular property of TNSALP (A116T), the
wild-type enzyme and this mutant protein were expressed in COS-1
cells ectopically. In contrast to TNSALP (W), TNSALP (A116T)
exhibited only negligible alkaline phosphatase activity as shown in
Fig. 1A. In agreement with the previous report [17], when co-
expressed with the wild enzyme, the activity of TNSALP (W) was
slightly suppressed by TNSALP (A116T), indicative of a dominant
negative effect of the latter (Fig. 1B). We have previously shown that
the wild-type enzyme is synthesized as a 66 kDa form with high
mannose-type oligosaccharides and is converted to a 80 kDa mature
form with complex-type oligosaccharides as it migrates from the
endoplasmic reticulum (ER) to the Golgi apparatus and ﬁnally isFig. 1. Transient expression of TNSALP mutant proteins in COS-1 cells. (A) COS-1 cells
were co-transfected with plasmids encoding TNSALP (W) or TNSALP (A116T) in various
ratios (1: 0, 0.9: 0.1, 0.5: 0.5, 0.1: 0.9, 0: 1, X axis). The transfected cells were
homogenized and assayed for alkaline phosphatase activity (expressed in % wild
enzyme, Y axis). The dotted line expects variation of the enzyme activity in the
recessive model. The values are the means of two independent experiments. (B) The
cells expressing TNSALP (W) (lanes 1 and 4), TNSALP (A116T) (lanes 2 and 5) or
TNSALP (D306V) (lanes 3 and 6) were steadily labeled with [35S] methionine/cysteine
for 3 h and lysed for immunoadsorption using anti-TNSALP antibody. Each immuno-
precipitate was analyzed by SDS-PAGE under a reducing (lanes 1–3) or non-reducing
condition (lanes 4–6), followed by ﬂuorography. An arrowhead indicates the top of the
resolving gel, while a double arrowhead indicates the top of the stacking gel. Left lane,
14C-methylated protein markers of 200, 97.5, 66, 46 kDa, from the top of the gel.localized on the cell surface as a GPI-anchored protein [7,20]. Besides,
these two molecular species are thought to exist as a non-covalently
assembled homodimer at least in transfected COS-1 cells [8].
Transfected cells were continuously labeled with [35S] methio-
nine/cysteine and then TNSALP was immunoprecipitated with an
antibody against TNSALP, followed by SDS-PAGE under a reduced or
non-reducing condition/ﬂuorography. Both the 66 and 80 kDa forms
were apparent in the cells expressing TNSALP (W) (Fig. 1, lane 1).
Similarly, the 80 kDa mature form was also found in the cells
expressing TNSALP (A116T) but not in the cells expressing TNSALP
(D306V) (Fig. 1, lanes 2 and 3). The aspartic acid at position 306 is
closely involved in the coordination of Ca2+ [21] and TNSALP (D306V)
is retained in the endoplasmic reticulum (ER), followed by ubiquiti-
nation and degradation in proteasomes [10]. Under a non-reducing
condition, a small amount of aggregates was detected even in the cell
expressing TNSALP (W) (Fig. 1, lane 4), probably due to shortage of
GPI precursors in transiently transfected cells [14]. On the other hand,
larger amounts of the aggregate were found in the cells expressing
TNSALP (A116T) or TNSALP (D306V) (Fig. 1, lanes 5 and 6).
3.2. Expression of TNSALP (A116T) in the Tet-On conditional expression
system
To determine if the aggregation of TNSALP (A116T) is due to an
excessive amount of this mutant generated in transiently transfected
cells, we attempted to establish Tet-On CHO K1 cells expressing
TNSALP (A116T) in response to doxycycline. Immunoﬂuorescence
pattern of Tet-On cells expressing TNSALP (A116T) was indistin-
guishable from that of the cells expressing TNSALP (W) (Fig. 2A). Both
TNSALP (W) and the TNSALP mutant were observed on the cell
surface only in the presence, but not in the absence of the antibiotic
(data not shown). In accordance with the result of transiently
transfected cells, TNSALP (A116T) lacked the enzyme activity as
shown in Fig. 2B. Next, the steady state expression level of TNSALP
(A116T) was assessed by immunoblotting. No protein band was
observed in the absence of doxycycline. Only the 80 kDa band was
detected in the cells expressing TNSALP (W) irrelevant to a reducing
or non-reducing conditions (Fig. 3A, lanes 2 and 6). In contrast, in
addition to the 80 kDa band a large amount of disulﬁde-bonded
aggregate appeared in the established cell expressing the mutant
protein (Fig. 3A, lanes 4 and 8). The presence of the 66 kDa form in the
cells expressing TNSALP (A116T) but not TNSALP (W) raises a
possibility that some part of TNSALP (A116T) exits from the ER only
at a reduced rate (Fig. 3A, lanes 4 and 8). To further examine the
aggregation state of TNSALP (W) and TNSALP (A116T), we subjected
each cell lysate to sucrose-density-gradient centrifugation and then
the fractions were analyzed by SDS-PAGE under a non-reducing
condition as shown in Fig. 3B. Most of TNSALP (W) was recovered in
fractions 7 and 8, where alcohol dehydrogenase (141 kDa) also
appeared, demonstrating that TNSALP (W) exists as a homodimeric
enzyme in Tet-On CHO. As SDS breaks this homodimeric structure
even in the absence of a reducing reagent, the dimer was not detected
on the gel. Markedly, a considerable fraction of TNSALP (A116T)
appeared with bovine serum albumin (68 kDa) (Fig. 3B, fractions 5
and 6), strongly indicating that TNSALP (A116T) is incapable of
assuming a correct tertiary structure and it tends to form disulﬁde-
bonded aggregates with heterogeneous sizes, instead of a dimer.
3.3. Biosynthetic study of TNSALP (A116T) in the established cell line
To examine the biosynthesis of TNSALP (A116T) in detail, pulse-
chase studies were carried out. The mutant protein is synthesized as
the 66 kDa form (Fig. 4, lane 1), however, the disulﬁde-bonded
aggregate started to appear during a 30-min pulse labeling time
(Fig. 4, lanes 1 and 5) and was present throughout the chase periods
(Fig. 4, lanes 6–8). This indicates that part of the newly synthesized
Fig. 3.Molecular size of TNSALP (W) and TNSALP (A116T). (A) The cells harboring pTRE2
encodingTNSALP (W)orTNSALP (A116T)were cultured for24 h in theabsence (lanes1, 3,
5, and 7) or presence (lanes 2, 4, 6, and 8) of doxycycline (1 μg/ml) and then the cell
homogenates (5 μg each) were analyzed by immunoblotting. An arrowhead indicates the
top of the resolving gel. (B) The established cells were induced to express TNSALP (W) or
TNSALP (A116T) like in (A). Each cell lysate was layered on the top of a linear sucrose
gradient consisting of 5% (w/w) sucrose and 35% (w/w) sucrose and centrifuged at 4 °C for
18 hat 163,000g. Each400 μl of fractionwas collected from the top of thegradient (total 12
Fig. 2. Expression of TNSALP (W) and TNSALP (A116T) in established Tet-On cells.
(A) Established cells harboring a pTRE2 encoding TNSALP (W) or TNSALP (A116T) were
cultured for 24 h in the presence of doxycycline (1 μg/ml) and processed for
immunoﬂuorescence using anti-TNSALP serum. (B) Like in (A), the cells were induced
to express TNSALP (W) or TNSALP (A116T). The cell homogenates were assayed for
alkaline phosphatase activity. The values are themeans of two independent experiments.
The speciﬁc activity was expressed in unit mg−1 protein. ND denotes not detected.
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to the Golgi. At a 30-min chase period, the 80 kDa form was clearly
detected under a reducing condition, while this mature form was less
clear under a non-reducing condition (Fig. 3, lanes 2 and 6), indicating
that a considerable amount of the 80 kDa form is in an aggregate state
in the established cell. Also, we noticed that newly synthesized
TNSALP (A116T) was decreased in its total intensity during the
experiment. Longer chase experiments suggest that TNSALP (A116T)
is less stable than the wild-type enzyme (Fig. 4B).fractions). Each 20 μl of the fractions was subjected to SDS-PAGE under a non-reducing
condition, followed by immunoblotting. Size marker: b (bovine serum albumin, 68 kDa,
a (alcohol dehydrogenase, 141 kDa) and c (catalase, 250 kDa).3.4. Cell surface appearance of disulﬁde-bonded aggregates of TNSALP
(A116T)
The presence of the 80 kDa mature form in the aggregate raises a
possibility that the high-molecular mass aggregate of TNSALP
(A116T) synthesized in the ER moves to the Golgi, acquires terminal
sugar residues during passage across the Golgi stack and ﬁnally is
conveyed to the cell surface. Next, we examined themolecular species
of TNSALP (A116T) exposed on the cell surface. Biosynthetic studies in
combination with cell surface biotinylation (Fig. 5A) or digestion with
PI-PLC (Fig. 5B) were performed. Not only the 80 kDa mature form,
but also the aggregate on and near the top of the gel were reactive
with a non-permeable biotinylation reagent. Furthermore, PI-PLC,
which cleaves the GPI anchor portion from the TNSALP molecule,
rendered the aggregate as well as the 80 kDa form released into the
medium, indicating that both molecular species reside on the cell
surface via the GPI anchor.3.5. TNSALP (W) and TNSALP (A116T) interact with each other
Dominantly transmitted TNSALPmutant protein including TNSALP
(A116T) are known to suppress the catalytic activity of TNSALP (W) to
various degrees when they are expressed together (Fig. 1A) [15–17].
However, direct association between TNSALP (W) and a dominant
negative TNSALP mutant protein has not been demonstrated to date.
To conﬁrm if TNSALP (W) and TNSALP (A116T) interact with each
other, we co-expressed secretory versions of TNSALP (W) and TNSALP
(A116T), which are modiﬁed by either a C-terminal his or ﬂagtags
(Fig. 6). TNSALP-his and TNSALP-ﬂag, which possess each tag
sequence instead of a C-terminal prosequence serving as a GPI anchor
signal sequence, are secreted into the medium as a dimeric enzyme
Fig. 4. Biosynthetic study of TNSALP (A116T). (A) The cells harboring pTRE2 encoding
TNSALP (A116T)were cultured for 14 h in the presence of 0.2 μg/ml of doxycycline before
experiments. The cells were pulse-labeled with [35S] methionine/[35S]cysteine for 30 min
(lanes 1, 5), and chased for 30 min (lanes 2 and 6), 1 h (lanes 3 and 7) and 2 h (lanes 4
and 8) as described inMaterials and methods. The immunoprecipitates were divided into
two equal portions, followed by SDS-PAGE under reducing (lanes 1–4) or non-reducing
condition (lanes5–8)/ﬂuorography. Left lane, the same 14C-methylatedproteinmarkers as
in Fig. 1. (B) The cells harboring pTRE2 encoding TNSALP (W) or TNSALP (A116T)
were cultured like in A. The cells were pulse-labeled for 30 min (lane 1 and 5) and
chased for 2 h (lane 6), 4 h (lanes 2 and 7), 6 h (lanes 3 and 8) and 8 h (lanes 4 and 8).
The immunoprecipitates were analyzed by SDS-PAGE under a reducing condition/
ﬂuorography. Left lane, the same 14C-methylated protein markers as in Fig. 1.
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whether TNSALP (W)-his was co-expressed with TNSALP (W)-ﬂag or
TNSALP (A116T)-ﬂag as assessed by direct immunoprecipitation using
anti-TNSALP (Fig. 6, lanes 1 and 2). However, the aggregate was
observed only in the culture medium of the cells expressing TNSALP
(W)-his and TNSALP (A116T)-ﬂag (Fig. 6, lane 2), implying that the
GPI anchor portion of TNSALP (A116T) is not responsible for the
formation of the aggregation. After being eluted with imidazole
from the Ni-NTA agarose, the aggregate was no more evident (Fig. 5,
lane 4). This is probably because TNSALP-ﬂag/TNSALP-ﬂag is not
absorbed to the resin among the three possible combinations [TNSALP
(W)-his/TNSALP (W)-his, TNSALP (W)-his/TNSALP (A116T)-ﬂag,
TNSALP (A116T) -ﬂag/TNSALP-ﬂag], resulting in the lower ratio of
TNSALP (A116T)-ﬂag to TNSALP (W)-his in the eluate. By a subsequent
immunoadsorption using the anti-ﬂag antibody, both the 80 kDa form
and the aggregate were captured (Fig. 6, lane 6), indicating that TNSALP(W) is able to interact with the 80 kDa form non-covalently and the
aggregate form of TNSALP (A116T) covalently, respectively.
4. Discussion
Based on 3D structure, TNSALP missense mutations associated
with hypophosphatasia are classiﬁed as 1) active site or active site
vicinity, 2) active site valley, 3) homodimer interface, 4) crown
domain, 5) calcium site or calcium site vicinity and 6) others [21]. So
far mutations with a dominant effect are restricted to three regions:
active site, homodimer and the crown domain [5]. A116T is assigned
to active site or active site vicinity, as serine at position 110 is an active
center of TNSALP [21]. The patients heterozygous for TNSALP (A116T)
displayed enamel hypoplasia and premature loss of fully rooted
primary anterior teeth [18], corresponding to adult or odonto
hypophosphatasia. Familial pedigree analysis demonstrated that
TNSALP (A116T) is dominantly transmitted [17,18]. Milder pheno-
types are probably attributed to its weak dominant negative effect on
thewild-type enzyme, as shown by co-expression study (Fig. 1A) [17].
Initially we thought that TNSALP (W) and TNSALP (A116T)monomers
form a simple non-covalently assembled hetero-dimer when they
are co-expressed, however, their interaction turned out to be more
complex.
To gain insight into the molecular mechanism of mild hypopho-
sphatasia caused by this particular dominant negative mutation, we
expressed TNSALP (A116T) as well as TNSALP (W) in COS-1 cells and
Tet-On CHO K1 cells. Cell surface appearance of TNSALP (A116T) is
indistinguishable from that of the wild enzyme as evaluated by
immunoﬂuorescence (Fig. 2). However, whether expressed in COS-1
cells transiently or Tet-On conditional expression system, TNSALP
(A116T) does not exhibit measurable alkaline phosphatase activity.
Besides, we found that TNSALP (A116T) tends to generate the
disulﬁde-bonded high-molecular mass aggregate in contrast to a
non-covalently assembled dimer structure of TNSALP (W) (Fig. 3A
and B). The aggregate form of TNSALP (A116T) appeared in the cell
within a 30-min pulse period, indicating that this aggregate is
produced in the ER (Fig. 4). Surprisingly, the disulﬁde-bonded
aggregate as well as the 66 kDa monomeric form of TNSALP
(A116T) are transport-competent and appear on the cell surface as
judged by cell surface biotinylation and PI-PLC digestion (Fig. 5).
To determine if TNSALP (A116T) is capable of interacting with
TNSALP (W), we took an advantage that TNSALP (W) can be secreted
as a homodimeric protein if its C-terminal prosequence serving as a
GPI anchor signal is appropriately replaced with his or ﬂag-tag [6,19].
Co-expression of TNSALP (W)-his and TNSALP (A116T)-ﬂag in COS-1
cells allowed us to demonstrate that the wild and the mutant TNSALP
interact with each other and are secreted into the medium (Fig. 6).
Although the sequential afﬁnity procedure is not quantitative, our
ﬁnding strongly suggests that TNSALP (W) and TNSALP (A116T) form
heterogeneous complexes and are anchored to the cell membrane via
GPI in patients carrying this particular dominantly transmitted
missense mutation.
Mornet's group has reported that dominant negative effects of
TNSALP mutant proteins on the wild-type enzyme vary from one
mutation to another [5,17]. TNSALP (D378V) and TNSALP (G63V)
inhibit the enzyme activity far more strongly than TNSALP (A116T)
does when co-expressed with TNSALP (W) [17]. On the other hand,
TNSALP (G249V) exerts its dominant effect without suppressing the
wild-type enzyme activity. TNSALP (G249V) likely sequesters the
wild-type enzyme at the Golgi, thus blocking its cell surface
appearance when co-expressed with the wild-type [22]. In this
study our results demonstrated that the substitution of alanine with
threonine at position 116 of TNSALP abrogates its tertiary structure.
TNSALP (A116T) exits as a monomeric polypeptide and its randomly
cross-linked aggregates via disulﬁde bonds. Considering that its
dominant negative effect is weak [17], it is likely that only a small
Fig. 5. Cell surface appearance of TNSALP (A116T). The cells harboring pTRE2 encoding TNSALP (A116T) were cultured for 14 h in the presence of 0.2 μg/ml of doxycycline and
subjected to cell surface biotinylation or PI-PLC digestion. (A) After being steadily labeled with [35S] methionine/cysteine for 3 h, the cells were washed and incubated with biotin
succinimidylester on ice. The cell lysate was immunoprecipitated using anti-TNSALP antibody. The immune complexes were divided into two equal parts: One part is directly
analyzed by SDS-PAGE under a non-reducing condition/ﬂuorography as total TNSALP, while the other was boiled, diluted and further incubated with streptavidin beads before
analysis (cell surface). Left lane, the same 14C-methylated protein markers as in Fig. 1. An arrowhead indicates the top of the resolving gel. (B) The cells were steadily labeled like in
(A) and further incubated in the absence (−) or presence (+) of PI-PLC in the DMEM. The cells and media were subjected to immunoprecipitation and then analyzed by SDS-PAGE
under a non-reducing condition/ﬂuorography. Left lane, the same 14C-methylated protein markers as in Fig. 1. An arrowhead indicates the top of the resolving gel.
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TNSALP (A116T) and entrapped in the aggregate when co-expressed,
while the rest of the TNSALP (W) is able to assemble into the nativeFig. 6. Interaction between TNSALP (W) and TNSALP (A116T). COS-1 cells were
transfected with cDNAs coding TNSALP (W)-his and TNSALP (W)-ﬂag (lanes 1, 3 and 5)
or TNSALP (W)-his and TNSALP (A116T)-ﬂag (lanes 2, 4 and 6). The cells were labeled
with [35S] methionine/cysteine for 8 h. Each culture medium was collected and divided
into three equal portions and was adsorbed with anti-TNSALP antibody (lanes 1 and 2),
Ni-chelate beads (lanes 3 and 4) or Ni-chelate beads and subsequently with anti-ﬂag
antibody (lanes 5 and 6). Left lane, the same 14C-methylated protein markers as in
Fig. 1. An arrowhead indicates the top of the resolving gel.homodimeric structure with a full enzyme activity. This result, along
with others, leads to a speculation that molecular mechanisms
whereby mild hypophosphatasia exerts its dominant negative effects
are highly variable.
Contrast to mild one with phenotypes of such as premature loss of
deciduous teeth and pseudo-fracture, severe hypophosphatasia
develops rickets or osteomalacia and sometimes hypercalcemia and
vitamin B6-dependent seizures [2–4]. The causative mutations for
severe forms are transmitted in a recessive trait and also found to
affect the TNSALPmolecule to varying degrees, resulting in a complete
loss or marked reduction of the catalytic function. Residual activities
of these TNSALP mutants even exhibit different catalytic properties
compared with the wild-type enzyme [6]. In addition, some TNSALP
mutants showed folding and trafﬁcking defects [7–12,20,23]. These
broad effects of the mutations on the TNSALP molecule contribute the
remarkably variable expressivity of this inborn error of metabolism.
Obviously, more works will be necessary to be done until we will get a
whole picture of molecular basis of hypophosphatasia.
There is no established medical treatment for hypophosphatasia.
However, several attempts have recently been made to aim at
developing the cure for this rare disease [24–26]. Especially, an
enzyme replacement therapy using a soluble human recombinant
TNSALP with a bone-targeted deca-aspartate motif is promising [24]
and clinical trials are underway in Canada and the United States.
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